National Biologics Facility
The National Biologics Facility (NBF) is a contract research organization supporting Australian researchers in the development, translation, and manufacturing of complex biological therapeutics. With state-of-the-art laboratories and a soon-to-be completed cGMP facility, NBF bridges the gap between basic research and clinical trials, offering services from discovery to Phase I clinical end points. Supported by Therapeutic Innovation Australia (TIA) and collaborating with various research institutes and industry partners, NBF specializes in protein and nucleic acid production, antibody discovery, process development, analytical testing, and vaccine development, including COVID-19 related research and manufacturing.
Industries
Nr. of Employees
medium (51-250)
National Biologics Facility
University of Technology, Broadway, Sydney NSW 2007
Services
End-to-end production of recombinant proteins from research scale through pilot/clinical (up to 200 L), including upstream and downstream processing and product isolation.
Synthesis and provision of high-quality nucleic-acid products for research, translational and industrial projects, with collaboration on packaging and delivery approaches.
Development of robust, phase-appropriate manufacturing processes and provision of tech transfer materials and models to support scale-up and transfer to GMP operations.
Comprehensive bioanalytical testing including identity, purity, potency, safety and stability assays to support in-process monitoring and release testing.
Antibody isolation using phage display and downstream engineering (reformatting, chimerisation, bispecifics, Fc engineering) to produce candidate therapeutic antibodies.
Support for design, conjugation, purification and characterisation of antibody-drug conjugates and other high-potency bioconjugates.
End-to-end production of recombinant proteins from research scale through pilot/clinical (up to 200 L), including upstream and downstream processing and product isolation.
Synthesis and provision of high-quality nucleic-acid products for research, translational and industrial projects, with collaboration on packaging and delivery approaches.
Development of robust, phase-appropriate manufacturing processes and provision of tech transfer materials and models to support scale-up and transfer to GMP operations.
Comprehensive bioanalytical testing including identity, purity, potency, safety and stability assays to support in-process monitoring and release testing.
Antibody isolation using phage display and downstream engineering (reformatting, chimerisation, bispecifics, Fc engineering) to produce candidate therapeutic antibodies.
Support for design, conjugation, purification and characterisation of antibody-drug conjugates and other high-potency bioconjugates.
Expertise Areas
- Recombinant protein production
- mRNA and DNA biomanufacturing
- Antibody discovery and engineering
- Antibody-drug conjugates and bioconjugation
Key Technologies
- Mammalian bioreactors (up to 200 L)
- Transient transfection and stable expression systems
- Phage display
- mRNA and DNA synthesis
News & Updates
Researches at the Doherty Institute and collaborators from UQ’s NBF and Biointelect are developing a novel therapeutic platform to combat viral pathogens with pandemic potential.
Queensland will be a major international hub for vaccine discovery and development with a $32 million partnership.
NBF is working with Dr Adam Wheatly and team from the Doherty Institute to deliver new platforms for antiviral biologics.
Researchers at the Doherty Institute and collaborators from UQ’s NBF are developing a platform to fight viral pathogens.
Researches at the Doherty Institute and collaborators from UQ’s NBF and Biointelect are developing a novel therapeutic platform to combat viral pathogens with pandemic potential.
Queensland will be a major international hub for vaccine discovery and development with a $32 million partnership.
NBF is working with Dr Adam Wheatly and team from the Doherty Institute to deliver new platforms for antiviral biologics.
Researchers at the Doherty Institute and collaborators from UQ’s NBF are developing a platform to fight viral pathogens.